C.Stim, a new intense pulsed light (IPL) system for dry eye treatment, has been launched as the next generation of IPL developed and manufactured by Quantel Medical – Lumibird Medical.
This IPL device, operating in the 610 – 1200 nanometre wavelength, is designed to treat meibomian gland dysfunction, significantly reduce the vicious cycle of chronic inflammation, and decrease demodex folliculorum in skin phototypes I through V.
Unlike other IPL devices, C.Stim uses a flash-lamp water-cooling system to guarantee homogenous energy throughout the treatment process, which maximises patient comfort
C.Stim is a user friendly, ergonomically designed device with intuitive software, that’s easily adaptable for any clinic or practice set-up. With reduced light absorption in melanin, the inflammatory response in patients is limited, resulting in an overall effective treatment outcome.
Unlike other IPL devices, C.Stim uses a flash-lamp water-cooling system to guarantee homogenous energy throughout the treatment process, which maximises patient comfort.
“Drawing on Quantel Medical years of experience in intense pulsed light in dermatology, we have now developed a new IPL device exclusively for use in ophthalmology, designed and manufactured by the Lumibird Medical group,” said Jean-Marc Gendre, CEO of Lumibird Medical.
“We are convinced that this new premium product of our Dry Eye Range will bring an innovative therapeutic solution to ophthalmologists confronted with the daily challenge of dry eye treatment.”
C.Stim is TGA approved and has CE marking.